Loading...
XSHE
301130
, Last price  
Name

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd

Chart & performance

D1W1MN
XSHE:301130 chart
P/E
—
P/S
—
EPS
0.29
Vol. 1Y
—
Shs. 5Y
4.77%
Rev. 5Y
-3.84%
Div Yld LY
—
Div Yld TTM
—
Revenues
235m
-8.41%
115,691,016151,305,120192,689,943203,556,480273,507,601280,203,467324,914,215286,318,718285,655,932285,655,931255,467,987255,467,986225,491,234256,405,242234,840,419
Net income
22m
-45.62%
28,254,25237,244,95440,318,06250,917,23045,625,29241,360,21354,613,47349,742,43752,019,09252,019,09840,723,02540,723,02750,502,42140,268,80121,900,019
CFO
49m
-10.37%
33,253,28436,409,3000031,347,54766,087,43565,933,47564,541,78159,013,81767,227,88654,385,94054,243,96248,621,245
Dividend
Jun 01, 20260.145 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd specializes in the comprehensive process of pharmaceutical goods, encompassing their research, development, production, and distribution. Its portfolio features therapeutic drugs addressing conditions such as anemia, mental health issues, cardiovascular ailments, and various cancers. The firm also supplies traditional Chinese medicines and essential raw materials. These medicinal products are available in oral solid forms and as freeze-dried powder for injections. Established in 1993, the company operates from its headquarters in Panshi, China.
IPO date
Feb 23, 2022
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT